These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32252075)

  • 1. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Moll S
    Ann Intern Med; 2020 Apr; 172(7):510. PubMed ID: 32252075
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Leong D; Wu PE
    Ann Intern Med; 2020 Apr; 172(7):509-510. PubMed ID: 32252074
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Ann Intern Med; 2019 Nov; 171(10):. PubMed ID: 31610579
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Cortés-Hernández J
    Ann Intern Med; 2020 Sep; 173(6):505-506. PubMed ID: 32926827
    [No Abstract]   [Full Text] [Related]  

  • 5. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 6. [Not Available].
    Bauersachs R; Schellong S; Stücker M; Oldenburg J; Kalka C; Scholz U; Lindhoff-Last E
    Hamostaseologie; 2019 Aug; 39(3):298-300. PubMed ID: 31404932
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
    Malec K; Broniatowska E; Undas A
    Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report].
    Joalland F; de Boysson H; Darnige L; Johnson A; Jeanjean C; Cheze S; Augustin A; Auzary C; Geffray L
    Rev Med Interne; 2014 Nov; 35(11):752-6. PubMed ID: 25217794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants in Antiphospholipid Syndrome: Too Early or Too Late?
    Wahl D; Dufrost V
    Ann Intern Med; 2019 Nov; 171(10):765-766. PubMed ID: 31610546
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome.
    Scanvion Q; Morell-Dubois S; Yelnik CM; Bene J; Gautier S; Lambert M
    Rheumatology (Oxford); 2018 May; 57(5):938-939. PubMed ID: 29373704
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply.
    Dufrost V; Risse J; Wahl D; Zuily S
    Rheumatology (Oxford); 2018 May; 57(5):939-940. PubMed ID: 29373692
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
    Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
    Sugie M; Iizuka N; Shimizu Y; Ichikawa H
    Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome. Dr. Hannah Cohen about the results of the RAPS trial (Lancet Haematol 2016; 3: e426-36).
    Rheumatology (Oxford); 2017 Sep; 56(9):e23. PubMed ID: 28859331
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
    Noel N; Dutasta F; Costedoat-Chalumeau N; Bienvenu B; Mariette X; Geffray L; Sene D; Chaidi RB; Michot JM; Fain O; Darnige L; Ankri A; Cacoub P; Piette JC; Saadoun D
    Autoimmun Rev; 2015 Aug; 14(8):680-5. PubMed ID: 25864630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.